During the third quarter, Cullen Frost Bankers Inc. boosted its position in Intuitive Surgical by 4.4%, acquiring an additional 3,450 shares to bring its total holdings to 82,056 shares, valued at approximately $36.7 million as of the latest SEC filing. Other notable shifts included Commerzbank Aktiengesellschaft FI, which added 752 shares (6.8% increase) to reach 11,802 shares worth about $5.3 million, and Whittier Trust Co. of Nevada Inc., which grew its stake by 8.8% through the purchase of 3,964 shares, bringing its total to 49,093 shares valued at roughly $22.2 million. Whittier Trust Co. also executed a separate 7.7% increase, acquiring 7,128 shares for a 100,093-share position worth $45.3 million. CIBC Asset Management Inc. and Robocap Asset Management Ltd. likewise expanded their stakes by 1.3% and 27.2%, respectively, underscoring sustained institutional confidence with 83.6% of ISRG held by such entities.

In its fiscal fourth quarter, Intuitive Surgical reported adjusted earnings of $2.53 per share, exceeding consensus estimates by $0.26, and generated revenue of $2.87 billion, surpassing expectations by $150 million. Year-over-year revenue growth of 18.8% was driven by higher system placements and consumable sales, while net margin of 28.4% reflected operational leverage. Return on equity stood at 15.2%. Management guided da Vinci procedure volume growth of 13% to 15% for fiscal 2026, down from 18% last year, attributing the moderation to capital pressures in certain European markets and potential reimbursement shifts in the U.S. Despite the tempered growth forecast, the company highlighted ongoing expansion in its consumables business and sustained demand for its flagship robotic platforms.

Insiders reduced their holdings modestly over the past quarter, with senior vice president Mark Brosius selling 464 shares and director Craig H. Barratt selling 750 shares, contributing to a total of 55,714 shares sold by executives for aggregate proceeds of $31.6 million. Meanwhile, the analyst community remains generally positive: one firm rates ISRG as a Strong Buy, fifteen maintain Buy ratings, nine have Holds and one assigns a Sell, resulting in a consensus view of Moderate Buy. Recent research notes have reiterated the company’s leadership in robotic surgery and affirmed the outlook for continued consumables growth and system replacement demand.